This site is intended for healthcare professionals
Drug information

AirFluSal Forspiro

POM
Read time: 34 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

AirFluSal Forspiro is indicated for use in adults 18 years of age and older only.

Asthma

AirFluSal Forspiro is indicated in the regular treatment of adults with severe asthma where use of a combination product (long-acting β2 agonist [LABA] and inhaled corticosteroid [ICS]) is appropriate:

Patients not adequately controlled on a lower strength corticosteroid combination product

or

Patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.

Chronic Obstructive Pulmonary Disease (COPD)

AirFluSal Forspiro is indicated for the symptomatic treatment of adults with COPD, with a forced expiratory volume in one second (FEV1) <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations and who have significant symptoms despite regular bronchodilator therapy.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).